ELOXX PHARMACEUTICALS, INC. Total Long-Term Debt
ELOXX PHARMACEUTICALS, INC. (ELOX) had Total Long-Term Debt of $1.00 million as of 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-09-11
- 2025-12-31: Long-term Debt $1.00M.
- 2023-09-30: Long-term Debt $4.62M.
- 2023-06-30: Long-term Debt $4.79M.
- 2023-03-31: Long-term Debt $4.74M.
| Period end | Long-term Debt |
|---|---|
| 2025-12-31 | $1.00M S-1 · filed 2026-09-11 |
| 2023-09-30 | $4.62M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.79M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $4.74M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $11.72M 10-K · filed 2023-03-31 |
| 2022-09-30 | $11.57M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $11.44M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $11.30M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $11.18M 10-K · filed 2022-03-30 |
| 2021-09-30 | $11.09M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $8.42M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $9.57M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $10.71M 10-K · filed 2021-03-12 |
| 2020-09-30 | $11.84M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $12.95M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $13.26M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $13.94M 10-K · filed 2020-03-06 |
| 2019-09-30 | $13.78M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $13.64M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $17.87M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |